Kymera Therapeutics, Inc. (KYMR) Down 6.5% — Do I Clear This From My Holdings?
Kymera Therapeutics, Inc. (KYMR) was last trading at $114.18 on Wednesday, down $3.49 from the prior close of $117.67 as a broad risk-off wave swept through development-stage biotech names and caught KYMR in its wake. The session's intraday low reached approximately $114.22 — a decline of roughly 6.5% at the worst point — before a partial recovery trimmed some of those losses. Even so, the stock remains under meaningful pressure relative to its 52-week high of $130.05, hit on June 25, 2026, sitting roughly 12.2% below that peak and reflecting how quickly sentiment can shift in clinical-stage names that have run hard in a short window.
Volume came in at approximately 617,375 shares, running below the 90-day average of 789,347. The lighter-than-average turnover is notable given the size of the intraday swing — it suggests the selling was not broadly distributed but concentrated enough to move the price sharply in a thinly contested session.
Why Kymera Therapeutics, Inc. Price is Moving Lower
Wednesday's weakness in KYMR is the result of a sector-level rotation out of biotech stocks rather than any company-specific negative. Investor's Business Daily reported that the Medical-Development Biotech group fell 4% on September 23, a sharp one-day reversal for a group that ranked third among all industry groups just one month earlier. The XBI biotech ETF was down roughly 0.7% in morning trading, but KYMR's decline was considerably steeper — a proof of how far the stock had already run and the vulnerability that comes with that kind of momentum buildup.
The scale of the pullback reflects where KYMR was sitting heading into Wednesday's session. After a strong run toward the 52-week high of $130.05, the stock had attracted profit-taking pressure that technical selling accelerated once the broader biotech tape turned negative. That dynamic — a high-momentum name meeting a risk-off day — produced an outsized move relative to the sector ETF. Still, the most recent company-specific analyst action remains constructive: Stifel maintained a Buy rating on September 22 and raised its price target from $132 to $152, a meaningful upward revision that keeps a near-term fundamental case on the table even as the stock pulls back.
Kymera's most recent quarterly results, reported on August 5 for Q2 ending June 30, add important context. The company posted EPS of negative $0.62 against a consensus estimate of negative $0.71, a $0.09 beat that signals tighter cash burn than the Street had modeled. Revenue came in at $65.0 million versus the $32.78 million consensus — a figure driven entirely by collaboration payments, including a $45 million fee from Gilead and a $20 million milestone from Sanofi. Revenue grew 465.2% year over year from $11.5 million, a striking headline number that nevertheless carries an important caveat: every dollar of that revenue originated from partnership arrangements, not product sales, leaving the top line subject to the timing and terms of future collaboration milestones rather than recurring commercial demand.
What is the Kymera Therapeutics, Inc. Rating - Should I Sell?
Weiss Ratings assigns KYMR a D- rating. Current recommendation is Sell.
The headline financials make the D- rating straightforward to understand. Revenue growth of 466.40% earns a Fair Growth Index — an impressive percentage on the surface, but Weiss Ratings correctly contextualizes it: the growth is milestone-driven collaboration revenue, not a sustainable product-revenue ramp, which limits how much weight it can carry in the overall assessment. The profit margin of -285.33% is the more telling number — it reflects the capital intensity of running multiple clinical programs simultaneously across STAT6, IRF5, IRAK4, and CDK2 degrader platforms, all at pre-commercial stage. That degree of cash consumption produces the Very Weak Efficiency Index, an honest representation of a company that is spending considerably more than it generates in revenue at this point in its development.
On the balance sheet side, the Excellent Solvency Index stands out as a genuine positive and deserves acknowledgment — Kymera has structured its partnership arrangements with Sanofi and Gilead in a way that provides meaningful non-dilutive capital, which has shored up its financial position and reduced near-term financing risk. The Good Total Return Index suggests the stock has delivered for shareholders who held through the broader appreciation cycle, though the Weak Volatility Index is a direct warning that those returns have come with significant price swings — exactly the kind of behavior on display Wednesday when the stock fell as much as 6.5% intraday on no company-specific news.
For investors assessing where Kymera sits within the Health Care sector, the rating picture is uniformly challenging. Moderna, Inc. (MRNA, D-), Natera, Inc. (NTRA, D-) and Revolution Medicines, Inc. (RVMD, D-) all carry the same D- rating. Chugai Pharmaceutical Co., Ltd. (CHGCF, D) and Zoetis Inc. (ZTS, D) rank marginally ahead of KYMR on the Weiss scale. None of these peers earn a Buy recommendation, and that cluster of low ratings reflects genuine sector-wide concern about development-stage risk, valuation, and the gap between clinical promise and commercial reality. Within that context, KYMR's D- places it at the weaker end of an already cautiously rated peer group.
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. (KYMR) is a Health Care company built around a targeted protein degradation platform that uses the body's own ubiquitin-proteasome system to selectively eliminate disease-causing proteins. Founded in 2015 and headquartered in Watertown, Massachusetts, the company has staked out a position at the frontier of a relatively new drug modality — one that promises to reach targets that conventional small molecules and biologics cannot. That scientific differentiation is the core of Kymera's competitive identity and the basis for the partnership interest it has attracted from major pharmaceutical companies.
The company's most advanced programs span immunology and oncology. KT-621, an oral STAT6 degrader, is in Phase 2b clinical trials targeting a broad range of inflammatory conditions including moderate to severe atopic dermatitis, asthma, COPD, and eosinophilic esophagitis. KT-485/SAR447971, an IRAK4 program developed in collaboration with Sanofi S.A., is in Phase 2 trials for hidradenitis suppurativa and atopic dermatitis — a partnership that provides both milestone funding and external validation of the platform. KT-579, an oral IRF5 degrader, is in Phase 1 trials targeting autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease. The company is also pursuing a CDK2 program with potential applications in breast cancer and other solid tumors.
Kymera's strategic alliance with Sanofi covers IRAK4 development outside oncology and immuno-oncology, while its Gilead collaboration provides additional non-dilutive capital through milestone and collaboration payments. These arrangements give the company financial runway without continuous equity issuance, a meaningful structural advantage for a clinical-stage operator managing multiple simultaneous programs. The breadth of the pipeline across both immunology and oncology reflects an intent to establish the targeted protein degradation platform as broadly applicable rather than disease-specific — an approach that, if validated, could support multiple commercial products over time.
Investor Outlook
Kymera Therapeutics, Inc. (KYMR) carries a Weiss Rating of D- (Sell), and Wednesday's intraday pullback of up to 6.5% on sector-driven selling underscores how exposed high-momentum clinical-stage names remain to broader risk-off moves, even in the absence of company-specific negative news. Investors will want to monitor upcoming clinical readouts across the KT-621 and KT-485 programs for the kind of data-driven catalysts that could shift the fundamental picture, while watching whether the Stifel $152 price target assumption holds as the biotech group works through its current pressure. See full rankings of all D--rated Health Care stocks inside the Weiss Stock Screener.
--